68 related articles for article (PubMed ID: 22870241)
1. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations.
Maeng CH; Lee J; van Hummelen P; Park SH; Palescandolo E; Jang J; Park HY; Kang SY; MacConaill L; Kim KM; Shim YM
PLoS One; 2012; 7(8):e41655. PubMed ID: 22870241
[TBL] [Abstract][Full Text] [Related]
2. Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
Zanaruddin SN; Yee PS; Hor SY; Kong YH; Ghani WM; Mustafa WM; Zain RB; Prime SS; Rahman ZA; Cheong SC
PLoS One; 2013; 8(11):e80229. PubMed ID: 24224046
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma.
Kuwabara S; Ajioka Y; Watanabe H; Hitomi J; Nishikura K; Hatakeyama K
Jpn J Cancer Res; 1998 Apr; 89(4):405-10. PubMed ID: 9617346
[TBL] [Abstract][Full Text] [Related]
4. Molecular and
Elfaki RM; Abdelaziz MS; Altayb HN; Munsoor MM; Gameel AA
F1000Res; 2018; 7():1741. PubMed ID: 31316750
[No Abstract] [Full Text] [Related]
5. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma.
Chiu CH; Ho HL; Doong H; Yeh YC; Chen MY; Chou TY; Tsai CM
Oncotarget; 2015 Apr; 6(10):8407-17. PubMed ID: 25823662
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in
Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722
[TBL] [Abstract][Full Text] [Related]
7. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.
Jabbour SK; Williams TM; Sayan M; Miller ED; Ajani JA; Chang AC; Coleman N; El-Rifai W; Haddock M; Ilson D; Jamorabo D; Kunos C; Lin S; Liu G; Prasanna PG; Rustgi AK; Wong R; Vikram B; Ahmed MM
J Natl Cancer Inst; 2021 Jun; 113(6):665-679. PubMed ID: 33351071
[TBL] [Abstract][Full Text] [Related]
8. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
9. Non-disruptive mutation in
Huang M; Jin J; Zhang F; Wu Y; Xu C; Ying L; Su D
Ann Transl Med; 2020 Mar; 8(6):316. PubMed ID: 32355760
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
[TBL] [Abstract][Full Text] [Related]
11. Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma.
Hatogai K; Fujii S; Kojima T; Daiko H; Nomura S; Doi T; Kitano S; Ohtsu A; Takiguchi Y; Yoshino T; Ochiai A
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2351-2361. PubMed ID: 28756492
[TBL] [Abstract][Full Text] [Related]
12.
Liu SY; Chen W; Chughtai EA; Qiao Z; Jiang JT; Li SM; Zhang W; Zhang J
World J Gastroenterol; 2017 Apr; 23(14):2585-2591. PubMed ID: 28465643
[TBL] [Abstract][Full Text] [Related]
13. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
Hatogai K; Fujii S; Kojima T; Daiko H; Doi T; Ohtsu A; Ochiai A; Takiguchi Y; Yoshino T
BMC Cancer; 2017 Jan; 17(1):36. PubMed ID: 28068934
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
Nakaji Y; Oki E; Nakanishi R; Ando K; Sugiyama M; Nakashima Y; Yamashita N; Saeki H; Oda Y; Maehara Y
J Cancer Res Clin Oncol; 2017 Jan; 143(1):151-160. PubMed ID: 27672042
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Kim HS; Lee SE; Bae YS; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Lee YC; Kim HR; Shim YM; Jewell SS; Kim H; Choi YL; Cho BC
Oncotarget; 2016 May; 7(21):30691-701. PubMed ID: 27095573
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma.
Kim JH; Lee JS; Kim EJ; Park KH; Kim KH; Yi SY; Kim HS; Cho YJ; Shin KH; Ahn JB; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Noh SH; Rha SY; Kim HS
Oncotarget; 2016 Apr; 7(17):24549-58. PubMed ID: 27016421
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC).
Wong CH; Ma BB; Hui CW; Tao Q; Chan AT
Am J Cancer Res; 2015; 5(12):3588-99. PubMed ID: 26885448
[TBL] [Abstract][Full Text] [Related]
18. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
[TBL] [Abstract][Full Text] [Related]
19. Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations.
Zhu J; Wang M; Zhu M; He J; Wang JC; Jin L; Wang XF; Xiang JQ; Wei Q
Sci Rep; 2015 Feb; 5():8250. PubMed ID: 25654238
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
Wang L; Shan L; Zhang S; Ying J; Xue L; Yuan Y; Xie Y; Lu N
PLoS One; 2014; 9(7):e103021. PubMed ID: 25054828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
